ReviewFrontiers in oncology2026
Evolving treatment strategies for HER2-altered non-small-cell lung cancer: the rise of TKIs and ADCs.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Does the ERBB/EGF Signaling Network Serve as a Nexus for Oncogenic Signals in Uveal Melanoma?Biomolecules · 2026Review
- [Mechanisms of Macrophage Efferocytosis-driven Remodeling of Lung Cancer Microenvironment Structure and Angiogenesis and Prospects for Clinical Intervention].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human epidermal growth factor receptor 2 (HER2) is an actionable oncogenic driver in a small subset of non-small cell lung cancer (NSCLC), occurring as gene mutations and less frequently as gene amplification or protein overexpression. Until recently, HER2-driven NSCLC lacked effective targeted treatments, and patients were managed with conventional chemotherapy and immunotherapy. However, the therapeutic landscape has rapidly evolved with the advent of novel HER2-directed antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs). Following the 2022 approval of the antibody-drug conjugate fam-trastuzumab deruxtecan (T-DXd), the therapeutic landscape of HER2-mutant NSCLC further expanded in 2025 with the regulatory approval of two highly selective oral HER2 tyrosine kinase inhibitors, zongertinib and sevabertinib. This review provides a comprehensive update on these emerging HER2-targeted therapies, including their clinical trial data, mechanisms of action, and comparative benefits over older pan-HER agents. We discuss the emerging therapeutic scope in HER2-"low" NSCLC, challenges with immunotherapy in HER2-driven tumors, and known resistance mechanisms to TKIs and ADCs. An evidence-based treatment algorithm is proposed, integrating new agents into current practice and addressing special considerations such as central nervous system (CNS) metastases. We also outline ongoing trials that may further shift first-line standards. In summary, recent breakthroughs in HER2-targeted TKIs and ADCs are transforming outcomes in this rare NSCLC subset, though optimizing sequencing, managing resistance, and improving patient selection through biomarker development remain priorities for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.